AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database

LY-CoV555 is a neutralizing antibody against SARS-CoV-2 that emerged from AbCelleras collaboration with Lilly.